AtriCure releases transcript of Q2 2026 earnings call

Reuters2026/07/24 15:13

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AtriCure’s Q2 2026 earnings call drew CEO Michael Carrel, CFO Angela Wirick, IR adviser Marissa Bych, analysts from Piper Sandler, BTIG, Canaccord, JPMorgan, Needham, Citizens JMP, Freedom, Oppenheimer.
Q2 revenue USD 153.6 million, up 12.8%; adjusted EBITDA USD 27.3 million; net income USD 9 million; gross margin 77.2%.
Raised 2026 outlook: revenue USD 602 million-USD 610 million; adjusted EBITDA USD 85 million-USD 89 million; EPS USD 0.05-USD 0.13; adjusted EPS USD 0.24-USD 0.32.
BoxX-NoAF trial passed 500 patients, targeting 960 by year-end; data readouts expected in H1 2027; PMA submission planned with about 1-year review.
Pain management grew 27% worldwide; cryoSPHERE MAX about 75% of US pain revenue; appendage management up 14%; MIS ablation stayed pressured by PFA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AtriCure releases transcript of Q2 2026 earnings call

You may also like

Crypto prices